Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Royal DSM NV (DSM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010863
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月20日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It provides products and services to animal and human health and nutrition, personal care, pharmaceuticals, dietary supplements, automotive, medical materials, food and beverages, packaging, electrical and electronics, coatings and paints, alternative energy, housing, life protection and bio-based materials markets. It has operations in Europe, Americas, Africa, the Middle East and Asia Pacific. DSM is headquartered at Heerlen, the Netherlands.

Royal DSM NV (DSM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Royal DSM NV, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Partnerships 16
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Equity Offering 24
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Debt Offering 28
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
Acquisition 31
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV – Key Competitors 42
Royal DSM NV – Key Employees 43
Royal DSM NV – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 47
Recent Developments 49
Strategy And Business Planning 49
Apr 03, 2017: Royal DSM Opens New Biotechnology Center in Delft, the Netherlands 49
Financial Announcements 50
Nov 02, 2017: DSM Reports Results First Nine Months 2017 50
May 02, 2017: DSM Q1 2017 Results 51
Feb 15, 2017: DSM reports 2016 results 52
Feb 14, 2017: DSM new presentation of accounts as from Q4 2016 56
Aug 02, 2016: DSM Q2 2016 results 57
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Royal DSM NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Royal DSM NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Royal DSM NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Royal DSM NV, Deals By Therapy Area, 2011 to YTD 2017 9
Royal DSM NV, Medical Devices Deals, 2011 to YTD 2017 10
Royal DSM NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Verdezyne Raises US$48 Million In Venture Financing 13
Arecor Raises Funds Through Venture Financing 15
Aerie Pharma Enters into R&D Agreement with Royal DSM 16
OptiBiotix Health Enters into Co-Development Agreement with Royal DSM 17
Royal DSM Forms Joint Venture With JLL Partners 18
DSM Enters Into Co-Development Agreement With AdeTherapeutics 20
Royal DSM Forms Joint Venture With Sinochem Group 21
Provexis Enters Into Co-Development Agreement With DSM Nutritional Products 23
Amyris Raises USD50 Million in Second and Final Tranche of Private Placement of Shares 24
Amyris Raises USD47 Million in First Tranche of Private Placement of Shares 25
ChromaDex Completes Private Placement Of Shares For US$3 Million 27
Royal DSM Completes Public Offering Of Bonds Due 2024 For US$684 Million 28
Royal DSM Announces Public Offering Of Notes Due 2019 For US$412.84 Million 29
Royal DSM Completes Private Placement Of Bonds Due 2019 For US$405 Million 30
i-Health to Acquire UP4 Probiotics from UAS Labs 31
Royal DSM To Acquire Aland Nutraceutical 32
DSM Completes Acquisition Of Fortitech, Nutraceutical Company, For US$634 Million 33
Royal DSM Completes Acquisition Of Ocean Nutrition Canada For US$532.7 Million 35
DSM Completes Acquisition Of Kensey Nash, Regenerative Medicine Company, For US$360 Million 37
Viocare Acquires DSM Personalized Nutrition From Royal DSM 39
Royal DSM Acquires Martek Biosciences 40
Royal DSM NV, Key Competitors 42
Royal DSM NV, Key Employees 43
Royal DSM NV, Other Locations 44
Royal DSM NV, Subsidiaries 44
Royal DSM NV, Joint Venture 47

★海外企業調査レポート[Royal DSM NV (DSM)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tidewater Inc (TDW):企業の財務・戦略的SWOT分析
    Summary Tidewater Inc (Tidewater) is an an petroleum service company that offers offshore supply vessels and marine support services. The company's services include transport and supply of offshore material; anchor handling, towing and positioning; personnel support; and assistance, salvage and reme …
  • CDI Corp:企業の戦略的SWOT分析
    CDI Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Debiopharm International SA:医療機器:M&Aディール及び事業提携情報
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Samchully Co Ltd (004690):企業の財務・戦略的SWOT分析
    Samchully Co Ltd (004690) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • China National Petroleum Corporation-エネルギー分野:企業M&A・提携分析
    Summary China National Petroleum Corporation (CNPC) is an integrated oil and gas company that produces and supplies oil and gas and petrochemical products. The company explores, develops and produces hydrocarbons in onshore and offshore areas of China, Canada, Africa, Central Asia and Russia, Latin …
  • Leica Biosystems Nussloch GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Leica Biosystems Nussloch Gmbh (Leica Biosystems) is a medical device company. The company provides histology and anatomical pathology workflow solutions. It offers histology equipment and consumables; immuo histochemistry, in situ hybridization, and fluorescence in situ hybridization (FISH) …
  • Synopsys Inc (SNPS):企業の財務・戦略的SWOT分析
    Synopsys Inc (SNPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Secure Energy Services Inc (SES):石油・ガス:M&Aディール及び事業提携情報
    Summary Secure Energy Services Inc. (Secure Energy) is an energy services company. It provides specialized services to upstream oil and natural gas companies operating in the Western Canadian Sedimentary Basin (WCSB) and North Dakota. The company assists these companies with the handling, processing …
  • Jadranka dd:企業の戦略・SWOT・財務分析
    Jadranka dd - Strategy, SWOT and Corporate Finance Report Summary Jadranka dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • SMART Global Holdings, Inc. (SGH):企業の財務・戦略的SWOT分析
    SMART Global Holdings, Inc. (SGH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Rio Tinto:戦略・SWOT・企業財務分析
    Rio Tinto - Strategy, SWOT and Corporate Finance Report Summary Rio Tinto - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Advanced Emissions Solutions, Inc. (ADES):企業の財務・戦略的SWOT分析
    Advanced Emissions Solutions, Inc. (ADES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Atrion Corp (ATRI):企業の財務・戦略的SWOT分析
    Atrion Corp (ATRI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Downer EDI Ltd (DOW)-エネルギー分野:企業M&A・提携分析
    Summary Downer EDI Limited (Downer) is a diversified services company. The company offers wide range of services such as transport infrastructure, engineering, utility, construction, and maintenance., It also provides mining services such as open-cut mining, crushing, underground mining operations, …
  • Hansard Global plc:企業の戦略・SWOT・財務情報
    Hansard Global plc - Strategy, SWOT and Corporate Finance Report Summary Hansard Global plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fresenius Kabi USA LLC:企業の戦略的SWOT分析
    Fresenius Kabi USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Vulcan Materials Company
    Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report Summary Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Infant Bacterial Therapeutics AB (IBT B):製薬・医療:M&Aディール及び事業提携情報
    Summary Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacil …
  • Population Genetics Technologies Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Population Genetics Technologies Ltd (Population Genetics) is a biotechnology company that offers diagnostic test solutions. The company provides products such as diagnostic test kits, HIV diagnostic test systems, and HCV diagnostic test systems. Its diagnostic test kits provide reagent assa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆